Teva To Divest Ratiopharm Products In Europe And Canada
Executive Summary
Teva agreed to divest ratiopharm's painkiller tramadol in Hungary and 15 other products in the Netherlands to win the European Commission's approval of its acquisition of the German generics company
You may also be interested in...
Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe
Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials